Biotech: Page 2


  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Emerging biotech

    Drugging RNA with pills: small molecules for a big frontier

    A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.

    By Sept. 6, 2022
  • A science lab with no workers
    Image attribution tooltip
    alvarez via Getty Images

    Finch to lay off 37% of staff after Takeda ends microbiome drug deal

    The company will cut 50 full-time positions and halt preclinical work on a pill for symptoms of autism in its second restructuring effort since April.  

    By Sept. 2, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass. Explore the Trendline
    Image attribution tooltip
    skynesher via Getty Images
    Trendline

    Emerging biotech

    A public market downturn has extended through 2022, forcing venture firms to build their drug startups more cautiously. Still, new biotech companies continue to emerge, as private investors have billions of available dollars to put to use.

    By BioPharma Dive staff
  • A 3D illustration of sickle cell anemia disease blood cells
    Image attribution tooltip
    Stock/Ezume Images via Getty Images

    With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug

    The target company, Forma Therapeutics, started as a developer of cancer drugs but has made the most progress in rare blood disorders, attracting Novo’s attention.

    By Updated Sept. 6, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Emerging biotech

    Biotech startup Ocean pivots from IPO to SPAC merger

    The blank-check deal gives Ocean another route to public markets after it struggled to price an initial public offering it revealed back in June 2021.

    By Aug. 31, 2022
  • Illustration of lung cancer
    Image attribution tooltip
    SciePro via Getty Images

    Jounce’s latest setback dampens outlook for another cancer immunotherapy target

    The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.  

    By Aug. 30, 2022
  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by Atlas Venture
    Q&A // Emerging biotech

    Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech

    In a wide-ranging conversation with BioPharma Dive, Booth, a prolific builder of new biotechs, said he’s starting to see positive signs for startups considering an IPO or private financing.

    By Aug. 30, 2022
  • A headshot of Akili CEO Eddie Martucci
    Image attribution tooltip
    Permission granted by Akili Inc.
    Q&A // Emerging biotech

    Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment

    With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.

    By Elise Reuter • Aug. 29, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    iStock via Getty Images

    Takeda ends deal with Finch as bumpy ride continues for microbiome drugs

    The pharma company terminated a collaboration that could’ve netted the biotech about $350 million. It’s the latest in a string of recent setbacks for microbiome drug developers.

    By Aug. 26, 2022
  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Dr_Microbe via Getty Images

    ElevateBio finds a new manufacturing home and long-term gene therapy partner in Pittsburgh

    The biotech signed a 30-year deal with the University of Pittsburgh to establish a gene and cell therapy manufacturing hub that’s being built with a $100 million grant.  

    By Kristen Jensen • Aug. 25, 2022
  • An illustration of cancer cells colored purple
    Image attribution tooltip
    Vitanovski via Getty Images
    Emerging biotech

    Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

    The pharma contributed to an $84 million round for the new cancer drugmaker, which attracted Novartis and Bristol Myers Squibb in an earlier fundraise. 

    By Aug. 25, 2022
  • An image of 3T Biosciences' San Francisco lab
    Image attribution tooltip
    Permission granted by 3T Biosciences
    Emerging biotech

    Backed by $40M, a biotech startup targets cancer with help from the immune system

    After several years in stealth, 3T Biosciences is launching publicly with plans to develop newer types of T cell receptor-based treatments.

    By Aug. 25, 2022
  • A rendering of a Sonoma Biotherapeutics research facility.
    Image attribution tooltip
    Courtesy of Sonoma Biotherapeutics

    ‘Treg’ startup Sonoma expands with plans for manufacturing plant

    The biotech, launched by immunologist Jeffrey Bluestone, is developing regulatory T cell therapies for autoimmune and inflammatory diseases.

    By Aug. 24, 2022
  • An illustration of a RAS protein
    Image attribution tooltip
    Selvanegra via Getty Images

    Biotech Erasca taps MD Anderson to help advance cancer drug work

    The five-year partnership is one of many inked between the cancer center and drugmakers like Erasca, which is targeting a cellular pathway linked to many types of tumors.

    By Aug. 23, 2022
  • A 3D visualization of Laronde's endless RNA, or eRNA
    Image attribution tooltip
    Permission granted by Laronde
    Emerging biotech

    Next-generation RNA technologies: making longer-lasting drugs with a broader reach

    At least nine biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

    By Updated Aug. 24, 2022
  • Man pointing at presentation board
    Image attribution tooltip
    Permission granted by QIAGEN
    Sponsored by QIAGEN

    Take the legwork out of drug toxicity screening

    Leveraging adverse outcome pathways (AOPs) just got easier. Learn how to be a pro.

    Aug. 22, 2022
  • Neuron
    Image attribution tooltip
    koto_feja via Getty Images

    Axsome rebounds to win FDA approval of depression drug

    A year after finding flaws in the biotech’s application, the regulator cleared a treatment some analysts view as a blockbuster-to-be, sending shares up.

    By Aug. 19, 2022
  • A 3D illustration of the hepatitis B virus.
    Image attribution tooltip
    iStock via Getty Images

    Bluejay raises $41M to bring hepatitis B drugs to clinical testing

    The biotech startup, which licensed two programs from Novartis, is part of a crowded field of drugmakers trying to develop new hepatitis B treatments. 

    By Aug. 19, 2022
  • A photo of Schrödinger chief financial officer Geoffrey Porges
    Image attribution tooltip
    Permission granted by Schrödinger

    Schrödinger names longtime biotech analyst Porges its CFO and top dealmaker

    After two decades researching biotechs at SVB Securities and AllianceBernstein, Geoffrey Porges will seek to grow the drug discovery specialist's network of partnerships.

    By Aug. 18, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna, after firing newly hired CFO, finds replacement in PerkinElmer executive

    The COVID-19 vaccine maker has appointed James Mock, currently PerkinElmer’s CFO, as its next finance head, three months after ousting Jorge Gomez from the role. 

    By Aug. 17, 2022
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead, with new results, doubles down on breast cancer drug

    The company has agreed to spend at least $280 million buying back rights to the drug, called Trodelvy, which were sold to Everest Medicines in 2019.

    By Aug. 16, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Ventyx touts early data for potential rival to Bristol Myers psoriasis drug

    The biotech plans to start Phase 2 studies for a drug it believes may more effectively hit its target than Bristol Myers’ deucravacitinib, a skin disease treatment regulators could approve next month. 

    By Aug. 16, 2022
  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Emerging biotech

    Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest

    The pharmaceutical giant has formed an alliance with Orna, investing $100 million in its Series B round in hopes the young biotech’s approach will lead to multiple new vaccines and drugs.

    By Aug. 16, 2022
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Emerging biotech

    Amid market turbulence, a Flagship startup pushes off an IPO with a new fundraise

    Senda Biosciences decided to raise a $123 million Series C round rather than test public markets with an initial offering, its top executive said.

    By Aug. 16, 2022
  • Electron microscope image of T regulatory cells interacting with antigen-presenting cells
    Image attribution tooltip
    NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
    Emerging biotech

    ‘Treg’ cell therapy: bringing CAR-T to autoimmune disease

    At least seven companies, including five richly funded startups, are developing cell-based treatments for inflammatory conditions, making it one of biotech’s most competitive fields. 

    By Aug. 16, 2022
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    ALS drug development

    Despite failed trial, Brainstorm asks FDA to approve ALS drug

    The move comes less than a month after the agency agreed to review Biogen’s tofersen — another ALS drug with a questionable record in clinical testing.

    By Updated Aug. 18, 2022